Simon Best emerged as one of the UK’s top life-sciences entrepreneurs more than a decade ago as CEO of Roslin Biomed, a Roslin Institute commercial offshoot that held intellectual property rights to the technologies behind Dolly the sheep, the first mammal cloned from an adult cell in 1997.

Two years later, Best merged the company with Geron to form Geron BioMed, then became a chief executive for various companies. Today, he is an entrepreneur-in-residence at venture-capital firm TVM Capital.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.